A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children

Yu Lung Lau; S. J.Rupert Vessey; Ivan S.F. Chan; Tsz Leung Lee; Li Min Huang; Chin Yun Lee; Tzou-Yien Lin; Bee Wah Lee; Kow Kwan; Siti M. Kasim; Christina Y. Chan; Karen M. Kaplan; Daniel J. Distefano; Anna L. Harmon; Amy Golie; Jonathan Hartzel; Jin Xu; Shu Li; Holly Matthews; Jerald C. Sadoff; Alan Shaw

doi:10.1016/S0264-410X(02)00245-1

A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children

Yu Lung Lau, S. J.Rupert Vessey, Ivan S.F. Chan, Tsz Leung Lee, Li Min Huang, Chin Yun Lee, Tzou-Yien Lin, Bee Wah Lee, Kow Kwan, Siti M. Kasim, Christina Y. Chan, Karen M. Kaplan, Daniel J. Distefano, Anna L. Harmon, Amy Golie, Jonathan Hartzel, Jin Xu, Shu Li, Holly Matthews, Jerald C. SadoffAlan Shaw

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

Abstract

This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.

Original language	English
Pages (from-to)	2942-2949
Number of pages	8
Journal	Vaccine
Volume	20
Issue number	23-24
DOIs	https://doi.org/10.1016/S0264-410X(02)00245-1
Publication status	Published - Jul 26 2002
Externally published	Yes

Keywords

Immunogenicity
Varicella vaccination
Varicella zoster virus

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0264-410X(02)00245-1

Cite this

Lau, Y. L., Vessey, S. J. R., Chan, I. S. F., Lee, T. L., Huang, L. M., Lee, C. Y., Lin, T-Y., Lee, B. W., Kwan, K., Kasim, S. M., Chan, C. Y., Kaplan, K. M., Distefano, D. J., Harmon, A. L., Golie, A., Hartzel, J., Xu, J., Li, S., Matthews, H., ... Shaw, A. (2002). A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children. Vaccine, 20(23-24), 2942-2949. https://doi.org/10.1016/S0264-410X(02)00245-1

Lau, YL, Vessey, SJR, Chan, ISF, Lee, TL, Huang, LM, Lee, CY, Lin, T-Y, Lee, BW, Kwan, K, Kasim, SM, Chan, CY, Kaplan, KM, Distefano, DJ, Harmon, AL, Golie, A, Hartzel, J, Xu, J, Li, S, Matthews, H, Sadoff, JC & Shaw, A 2002, 'A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children', Vaccine, vol. 20, no. 23-24, pp. 2942-2949. https://doi.org/10.1016/S0264-410X(02)00245-1

@article{0d76ad1b239c4f47ab9801485663cabf,

title = "A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX{\texttrademark} in healthy children",

abstract = "This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX{\texttrademark} [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX{\texttrademark}, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.",

keywords = "Immunogenicity, Varicella vaccination, Varicella zoster virus",

author = "Lau, {Yu Lung} and Vessey, {S. J.Rupert} and Chan, {Ivan S.F.} and Lee, {Tsz Leung} and Huang, {Li Min} and Lee, {Chin Yun} and Tzou-Yien Lin and Lee, {Bee Wah} and Kow Kwan and Kasim, {Siti M.} and Chan, {Christina Y.} and Kaplan, {Karen M.} and Distefano, {Daniel J.} and Harmon, {Anna L.} and Amy Golie and Jonathan Hartzel and Jin Xu and Shu Li and Holly Matthews and Sadoff, {Jerald C.} and Alan Shaw",

note = "Funding Information: This study was supported by a grant from Merck & Co. Inc.",

year = "2002",

month = jul,

day = "26",

doi = "10.1016/S0264-410X(02)00245-1",

language = "English",

volume = "20",

pages = "2942--2949",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "23-24",

}

TY - JOUR

T1 - A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children

AU - Lau, Yu Lung

AU - Vessey, S. J.Rupert

AU - Chan, Ivan S.F.

AU - Lee, Tsz Leung

AU - Huang, Li Min

AU - Lee, Chin Yun

AU - Lin, Tzou-Yien

AU - Lee, Bee Wah

AU - Kwan, Kow

AU - Kasim, Siti M.

AU - Chan, Christina Y.

AU - Kaplan, Karen M.

AU - Distefano, Daniel J.

AU - Harmon, Anna L.

AU - Golie, Amy

AU - Hartzel, Jonathan

AU - Xu, Jin

AU - Li, Shu

AU - Matthews, Holly

AU - Sadoff, Jerald C.

AU - Shaw, Alan

N1 - Funding Information: This study was supported by a grant from Merck & Co. Inc.

PY - 2002/7/26

Y1 - 2002/7/26

N2 - This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.

AB - This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.

KW - Immunogenicity

KW - Varicella vaccination

KW - Varicella zoster virus

UR - http://www.scopus.com/inward/record.url?scp=0037178307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037178307&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00245-1

DO - 10.1016/S0264-410X(02)00245-1

M3 - Article

C2 - 12126906

AN - SCOPUS:0037178307

SN - 0264-410X

VL - 20

SP - 2942

EP - 2949

JO - Vaccine

JF - Vaccine

IS - 23-24

ER -

A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this